Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Multicenter Study of TAS-102 in Combination With Irinotecan in Patients With Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma After at Least One Line of Treatment With a Fluoropyrimidine and Platinum Containing Regimen

NCT04074343 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT04074343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04074343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Multicenter Study of TAS-102 in Combination With Irinotecan in Patients With Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma After at Least One Line of Treatment With a Fluoropyrimidine and Platinum Containing Regimen
Lead sponsor
University of California, Irvine
Phase
Phase 1
Overall status
Completed
Start date
August 26, 2019
Completion date
July 21, 2022
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal cancer